Health Trials

Clinical trials

7

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants

This study aims to evaluate the effects of food or ethnicity on the pharmacokinetics and safety/tolerability of JPI-547 after a single oral administration in healthy male Korean, Caucasian, and Chinese participants.

Participants needed: 36
Trial details
Phase: Phase 1Age: 19-50Biological sex: MaleType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: May 6, 2026Locations: 1
Eligibility criteria

Healthy Korean, Caucasian, or Chinese male participants aged 19 to 50 years at s... [+3]

Clinically significant medical or surgical history [+11]

Read more
Status: Recruiting

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer

Participants needed: 71
Trial details
Phase: Phase 1, Phase 2Age: 19-79Biological sex: AllType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: Apr 13, 2026Locations: 4
Eligibility criteria

Histologically or cytologically confirmed inoperable locally advanced or metasta... [+7]

Those with a history of severe hypersensitivity to the investigational product o... [+29]

Read more
Status: Not yet recruiting

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients

Participants needed: 81
Trial details
Phase: Phase 2Age: 19+Biological sex: FemaleType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: Jan 27, 2026Locations: 1
Eligibility criteria

Histologically or cytologically confirmed recurrent ovarian cancer, fallopian tu... [+5]

Patients with a history of severe drug hypersensitivity or hypersensitivity to t... [+6]

Read more
Status: Not yet recruiting

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer

Participants needed: 49
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: Jan 23, 2026Locations: 1
Eligibility criteria

Patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ)... [+2]

Patients with a confirmed specific medical history or past surgical history [+9]

Read more
Status: Recruiting

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Participants needed: 96
Trial details
Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: Dec 4, 2025Locations: 1
Eligibility criteria

Healthy subject aged ≥ 19 years to < 65 years at the time of screening [+2]

Subject who has a clinically significant history of disease in the liver, kidney... [+5]

Read more
Status: Not yet recruiting

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD

Participants needed: 321
Trial details
Phase: Phase 3Age: 19-75Biological sex: AllType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: Sep 8, 2025
Eligibility criteria

Subjects who have experienced both heartburn and acid regurgitation [+2]

Subjects who have significant gastrointestinal diseases or procedures affecting... [+6]

Read more
Status: Recruiting

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.

Participants needed: 364
Trial details
Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Onconic Therapeutics Inc.Updated: Nov 1, 2024Locations: 1
Eligibility criteria

Adult male/female aged 19 years or older as of the date of obtaining consent [+3]

Those who cannot undergo upper gastrointestinal endoscopy [+5]

Read more